Document:

<PAGE>
                                                                    Exhibit 10.4

Amendment One to Development Agreement                               Page 1 of 7

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                              AMENDMENT ONE
                                    TO

                          DEVELOPMENT AGREEMENT

    This Amendment One made as of the day last subscribed below ("Effective
Date") between SRI International, a California, non-profit and public benefit
corporation, having a place of business located at 333 Ravenswood Avenue, Menlo
Park, CA 94025 (hereinafter "SRI") and Lipid Sciences Incorporated, a Delaware
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

      WHEREAS, SRI and LSI have entered in to a development agreement having an
effective date of October 6, 2000 (hereinafter "Development Agreement") and
which the parties hereby amend; and

      WHEREAS, the parties intend that this Amendment One provides an extension
of the Phase I Development Period of the Development Agreement as originally
executed

      NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1. For consistency and unless otherwise defined herein all initially capitalized
   terms shall have the meaning set forth in the Development Agreement.

2. The parties hereby agree that the Phase I Development Period shall mean the
   period commencing on October 6, 2000 and unless terminated earlier as
   provided the Development Agreement or extended by the mutual written
   agreement of the parties, shall expire on March 30, 2001.

3. The parties hereby agree that the research fee authorized by LSI for the
   Phase I Development Period as set forth in 2.2.1 of the Development
   Agreement, has not been changed.

4. The parties hereby agree that the Development Plan for Phase I shall be
   amended as follows and a copy of the amended Development Plan is attached
   hereto as Exhibit A: (i) Task 10 is deleted and may be included in Phase II
   depending on the experimental results of Task 9; (ii) Task 11 Output with
   respect to the record of a preliminary design review has been deleted from
   Phase I and shall be included in Phase II; (iii) Tasks 14-18 are to be
   deleted from Phase I and shall be included in Phase II; and. (iv) Tasks 20
   and 21 shall be added to the Development Plan for Phase I to cover the single
   solvent work and material compatibility.

5. Section 3.5 shall be amended to read:

        "3.5.  License Grant to SRI for Internal Research Purposes. LSI hereby
        grants to SRI a perpetual, non-exclusive, royalty-free license (without
        the right to grant sublicenses) to practice and use the Development
        Program Intellectual Property for Internal Research Purposes."

6. Section 11.1, Notices, the LSI telephone number for Phil Radlick shall be
   amend to read "925-249-4010" and the facsimile number to read "925-249-4040".
<PAGE>
Amendment One to Development Agreement                               Page 2 of 7

*CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Unless expressly amended by this Amendment One, all other terms and conditions
of the Development Agreement shall remain in full force and effect.

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

SRI:                                       LSI:
SRI International                          Lipid Sciences, Incorporated

By /s/ Valerie J. Hooper                   By: /s/ Phil Radlick
  -------------------------                   ----------------------------------
    Valerie J. Hooper                               Phil Radlick, Ph.D.
    Associate Director,                       President/ Chief Executive Officer
    Corporate Development

Date: March 8, 2001                         Date: March 8, 2001

<PAGE>
Amendment One to Development Agreement                               Page 3 of 7

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                EXHIBIT A

              AMENDED TASKS FOR DEVELOPMENT PLAN FOR PHASE 1

                                   [*]

<PAGE>
                                                                     Page 4 of 7

                     Amendment One to Development Agreement

* Certain Information in this Exhibit has been omitted and filed separately
with the Securities and Exchange Commission. Confidential Treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]
<PAGE>

                                                                     Page 5 of 7

                     Amendment One to Development Agreement

*Certain Information in this Exhibit has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]

<PAGE>
                                                                     Page 6 of 7

                     Amendment One to Development Agreement
*Certain information in this Exhibit has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]

<PAGE>
                                                                     Page 7 of 7

                     Amendment One to Development Agreement

*Certain information in this Exhibit has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]<PAGE>
                                                                    Exhibit 10.6

Amendment Three Phase II to Development Agreement                    Page 1 of 5

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                            AMENDMENT THREE PHASE II
                                       TO
                              DEVELOPMENT AGREEMENT

    This Amendment Three made as of May 12, 2001 ("Effective Date") between SRI
International, a California, non-profit and public benefit corporation, having a
place of business located at 333 Ravenswood Avenue, Menlo Park, CA 94025
(hereinafter "SRI") and Lipid Sciences Incorporated, a Delaware corporation,
having a place of business located at 7068 Koll Center Parkway, Suite 401,
Pleasanton, CA 94566 (hereinafter "LSI").

      WHEREAS, SRI and LSI have entered into a development agreement having an
effective date of October 6, 2000 and an Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001 (hereinafter individually and
collectively "Development Agreement") and which the parties hereby amend; and

      WHEREAS, the parties intend that this Amendment Three provides for the
details of Phase II Development Plan of the Development Agreement.

      NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.    For consistency and unless otherwise defined herein all initially
      capitalized terms shall have the meaning set forth in the Development
      Agreement.

2.    Attached hereto as Exhibit A is the Phase II Development Plan, which
      consists of a list of definition of terms used throughout the Development
      Plan, Project Cost and Design/Cost Assumptions, LSI furnished resources,
      Statement of Work, Milestones for Single and Multi-Solvent Systems,
      Acceptance Criteria for each System, the System Specification number REV
      -1 dated June 15, 2001 and the Microsoft Project Plan dated June 1, 2001.

3.    The Effective Date of this Amendment is May 12, 2001, the execution date
      of this Amendment is the date last subscribed below.

4.    Paragraph 1.2 shall be amended to include the following: "Phase II
      Development Period shall extend until thirty days following the completion
      of all milestones for the second system, unless terminated earlier as
      provided in the Agreement or extended by mutual written agreement of the
      parties."
<PAGE>
Amendment Three Phase II to Development Agreement                    Page 2 of 5

5.    Paragraph 2.2.1 shall be amended to include the following: "In
      consideration for the services to be performed by SRI in Phase II of the
      Development Program, as described in the Phase II Development Plan, LSI
      shall pay SRI fees not-to-exceed six million three hundred thousand
      dollars ($6,300,000), inclusive of the advanced deposit payment under
      Section 2.2.4 as amended below."

6.    Paragraph 2.2.2 shall be amended to include the following: "During the
      remainder of Phase II SRI shall not expend more than six hundred thousand
      dollars ($600,000) in any one month pursuant to the Phase II Development
      Plan attached hereto, without the prior written consent of LSI."

7.    Paragraph 2.2.4 of the Development Agreement, second sentence beginning on
      line 4 through the end of the paragraph shall be deleted in its entirety
      and replaced with the following sentence:

            "In lieu of LSI providing an advance payment, the parties agree that
            SRI will invoice LSI weekly, for work conducted from Sunday through
            Saturday of each week. SRI will provide such invoice in writing to
            LSI by the close of business on any Wednesday thereafter and SRI
            will receive payment from LSI by the Friday immediately following
            receipt of the SRI invoice. Each such invoice shall identify the
            total cost of labor and the number of employees used by SRI for the
            period of time being invoiced. In the event any such Friday is a
            Federal holiday or the Friday following Thanksgiving Day, then the
            payment shall be due on the next following business day. Should LSI
            dispute any portion of the SRI invoice, which it believes in good
            faith to be erroneous, then LSI shall provide an explanation of the
            disputed portion to SRI by the payment date along with payment for
            the undisputed portion of the invoice and the parties shall promptly
            negotiate in good faith to resolve the dispute. In the event that
            any LSI payment is not timely paid, then SRI may at its option,
            cease all work under the Phase II Development Plan until such time
            as the LSI payment, which is due is paid in full. If SRI stops work
            for nonpayment or late payment reasons, then the Parties agree to
            negotiate in good faith an adjustment to the deliverable dates,
            and/or costs caused as a direct result of having to stop work for
            nonpayment. Any revised cost shall exclude idle time caused by
            having to stop work.

8.    The parties agree that Paragraphs 2.2.5 through 2.2.8 of the Development
      Agreement shall not apply to Phase II.

9.    Exhibit C of the Development Agreement, under the subtitle Exercise
      Section (a) subsection (ii) should be deleted in its entirety and replaced
      with the following:

            "Upon meeting the Phase II Milestone Design History File Transfer &
            Final Prototype Delivery for the first system, the Warrant will
            become exercisable with respect to one hundred and seventy-five
            thousand (175,000) shares of LSI Common Stock. Upon meeting the
            Phase II Milestone Design History File Transfer & Final Prototype
            Delivery for the second system, the Warrant will
<PAGE>
Amendment Three Phase II to Development Agreement                    Page 3 of 5

            become exercisable with respect to one hundred and seventy-five
            thousand (175,000) shares of LSI Common Stock. In the event that LSI
            discontinues development and design of one of the systems under
            Phase II, then all three hundred and fifty thousand (350,000) shares
            of LSI common stock shall be exercisable upon SRI meeting Design
            History File Transfer & Final Prototype Delivery Milestone for the
            other system."

10.   LSI is currently involved in entering into a merger with a third party. In
      the event that such a merger does not take place, then the parties
      understand that it is probable that LSI will request SRI to decrease its
      monthly spend rate amount. SRI will comply with such a request. Both
      parties agree to meet and negotiate in good faith revisions to the Phase
      II Development Plan Schedule, Statement of Work (Tasks) and an equitable
      adjustment to the total cost of Phase II, recognizing that changes to the
      proposed spend rate may result in higher program costs.

11.   The parties agree that due to unforeseen delays the end date Milestones,
      previously agreed to by the parties, the Production Prototype based on
      System Specification & Product Specs Assembled for the Single Solvent
      System of February 4, 2002 and the Production Prototype based on System
      Specification & Product Specs Assembled the Multi-Solvent System of July
      25, 2002; shall be extended by not more than sixty (60) days and all other
      Milestones will be adjusted appropriately as described below. The parties
      further agree that the project management plan is being changed from a
      task based project management to critical chain project management.
      Critical chain project management involves the optimization of technical
      abilities of the SRI team to achieve short-term goals on which the entire
      team is focused. As a result of such change the Milestones as identified
      herein will be reordered and reorganized by the project leader from SRI,
      Tom Low, and the V.P. of Product Development of LSI, Marc Bellotti as
      necessary throughout the Phase II Development Period.

12.   The parties each recognize that there are technical risks associated with
      the Phase II Development Plan, (e.g. TBD's in the attached Systems
      Specification, Rev 1, June 15, 2001) and that there may be technical
      issues, which arise that are outside of the current scope of work. In the
      event that such technical issues arise, SRI shall promptly identify such
      technical issue in writing to LSI. Such writing shall detail SRI's
      proposal for resolving the technical issue, including the time-line
      changes and effect on overall project cost, as well as an approximate time
      within which LSI needs to respond to SRI to resolve the issue. LSI shall
      then timely provide a written response to SRI with its instruction on how
      to proceed with respect to the technical issue being addressed.

13.   In the event that the Agreement is terminated by LSI pursuant to Paragraph
      6 of the Development Agreement then LSI agrees that it shall pay for all
      cost incurred as of the notice date of termination and that the parties
      shall negotiate in good faith to agree on reasonable costs to be covered
      by LSI and deliverables from SRI in order for to close down the Phase II
      Development Plan.
<PAGE>
Amendment Three Phase II to Development Agreement                    Page 4 of 5

14.   Unless expressly amended by this Amendment Three, all other terms and
      conditions of the Development Agreement shall remain in full force and
      effect.

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

SRI:                                      LSI:
SRI International                         Lipid Sciences, Incorporated

By: /s/ V. Rene Harmount                    By: /s/ Phil Radlick
    ----------------------------                ----------------------------
    V. Rene Harmount                            Phil Radlick, Ph.D.
Group Manager, Contract Administration      President & Chief Executive Officer

Date: July 25, 2001                         Date: July 25, 2001
    ----------------------------                ----------------------------
<PAGE>
Amendment Three Phase II to Development Agreement                    Page 5 of 5

                                Exhibit A
                        Development Plan Phase II

                                  [ * ]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]